Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia Overexpression
Williams–Beuren syndrome (WBS) is a rare neurodevelopmental disorder characterized by a distinctive cognitive phenotype for which there are currently no effective treatments. We investigated the progression of behavioral deficits present in WBS complete deletion (CD) mice, after chronic treatment wi...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.670785/full |
id |
doaj-be145bfe15ff483e9bcba89e641ade63 |
---|---|
record_format |
Article |
spelling |
doaj-be145bfe15ff483e9bcba89e641ade632021-08-03T07:34:56ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-08-011210.3389/fphar.2021.670785670785Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia OverexpressionPaula Ortiz-Romero0Alejandro González-Simón1Gustavo Egea2Gustavo Egea3Luis A. Pérez-Jurado4Luis A. Pérez-Jurado5Luis A. Pérez-Jurado6Victoria Campuzano7Victoria Campuzano8Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, SpainDepartament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, SpainDepartament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi I Sunyer, IDIBAPS-UB, Barcelona, SpainUnitat de Genètica, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, SpainCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Barcelona, SpainServei de Genètica, Hospital del Mar, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, SpainDepartament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, SpainCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Barcelona, SpainWilliams–Beuren syndrome (WBS) is a rare neurodevelopmental disorder characterized by a distinctive cognitive phenotype for which there are currently no effective treatments. We investigated the progression of behavioral deficits present in WBS complete deletion (CD) mice, after chronic treatment with curcumin, verapamil, and a combination of both. These compounds have been proven to have beneficial effects over different cognitive aspects of various murine models and, thus, may have neuroprotective effects in WBS. Treatment was administered orally dissolved in drinking water. A set of behavioral tests demonstrated the efficiency of combinatorial treatment. Some histological and molecular analyses were performed to analyze the effects of treatment and its underlying mechanism. CD mice showed an increased density of activated microglia in the motor cortex and CA1 hippocampal region, which was prevented by co-treatment. Behavioral improvement correlated with the molecular recovery of several affected pathways regarding MAPK signaling, in tight relation to the control of synaptic transmission, and inflammation. Therefore, the results show that co-treatment prevented behavioral deficits by recovering altered gene expression in the cortex of CD mice and reducing activated microglia. These findings unravel the mechanisms underlying the beneficial effects of this novel treatment on behavioral deficits observed in CD mice and suggest that the combination of curcumin and verapamil could be a potential candidate to treat the cognitive impairments in WBS patients.https://www.frontiersin.org/articles/10.3389/fphar.2021.670785/fullWilliams–Beuren syndromecurcuminverapamilmiceactivated gliabehavior |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Paula Ortiz-Romero Alejandro González-Simón Gustavo Egea Gustavo Egea Luis A. Pérez-Jurado Luis A. Pérez-Jurado Luis A. Pérez-Jurado Victoria Campuzano Victoria Campuzano |
spellingShingle |
Paula Ortiz-Romero Alejandro González-Simón Gustavo Egea Gustavo Egea Luis A. Pérez-Jurado Luis A. Pérez-Jurado Luis A. Pérez-Jurado Victoria Campuzano Victoria Campuzano Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia Overexpression Frontiers in Pharmacology Williams–Beuren syndrome curcumin verapamil mice activated glia behavior |
author_facet |
Paula Ortiz-Romero Alejandro González-Simón Gustavo Egea Gustavo Egea Luis A. Pérez-Jurado Luis A. Pérez-Jurado Luis A. Pérez-Jurado Victoria Campuzano Victoria Campuzano |
author_sort |
Paula Ortiz-Romero |
title |
Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia Overexpression |
title_short |
Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia Overexpression |
title_full |
Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia Overexpression |
title_fullStr |
Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia Overexpression |
title_full_unstemmed |
Co-Treatment With Verapamil and Curcumin Attenuates the Behavioral Alterations Observed in Williams–Beuren Syndrome Mice by Regulation of MAPK Pathway and Microglia Overexpression |
title_sort |
co-treatment with verapamil and curcumin attenuates the behavioral alterations observed in williams–beuren syndrome mice by regulation of mapk pathway and microglia overexpression |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2021-08-01 |
description |
Williams–Beuren syndrome (WBS) is a rare neurodevelopmental disorder characterized by a distinctive cognitive phenotype for which there are currently no effective treatments. We investigated the progression of behavioral deficits present in WBS complete deletion (CD) mice, after chronic treatment with curcumin, verapamil, and a combination of both. These compounds have been proven to have beneficial effects over different cognitive aspects of various murine models and, thus, may have neuroprotective effects in WBS. Treatment was administered orally dissolved in drinking water. A set of behavioral tests demonstrated the efficiency of combinatorial treatment. Some histological and molecular analyses were performed to analyze the effects of treatment and its underlying mechanism. CD mice showed an increased density of activated microglia in the motor cortex and CA1 hippocampal region, which was prevented by co-treatment. Behavioral improvement correlated with the molecular recovery of several affected pathways regarding MAPK signaling, in tight relation to the control of synaptic transmission, and inflammation. Therefore, the results show that co-treatment prevented behavioral deficits by recovering altered gene expression in the cortex of CD mice and reducing activated microglia. These findings unravel the mechanisms underlying the beneficial effects of this novel treatment on behavioral deficits observed in CD mice and suggest that the combination of curcumin and verapamil could be a potential candidate to treat the cognitive impairments in WBS patients. |
topic |
Williams–Beuren syndrome curcumin verapamil mice activated glia behavior |
url |
https://www.frontiersin.org/articles/10.3389/fphar.2021.670785/full |
work_keys_str_mv |
AT paulaortizromero cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression AT alejandrogonzalezsimon cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression AT gustavoegea cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression AT gustavoegea cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression AT luisaperezjurado cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression AT luisaperezjurado cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression AT luisaperezjurado cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression AT victoriacampuzano cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression AT victoriacampuzano cotreatmentwithverapamilandcurcuminattenuatesthebehavioralalterationsobservedinwilliamsbeurensyndromemicebyregulationofmapkpathwayandmicrogliaoverexpression |
_version_ |
1721223610903822336 |